Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study

Lary J. Kilton*, Al B. Benson, Alice Greenberg, Patricia Johnson, Charles Shapiro, Richard Blough, Suzanne French, Linda Weidner

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.

Original languageEnglish (US)
Pages (from-to)201-204
Number of pages4
JournalInvestigational New Drugs
Volume10
Issue number3
DOIs
StatePublished - Aug 1 1992

Fingerprint

fludarabine phosphate
Pancreas
Appointments and Schedules
Adenocarcinoma
Kidney
Leukopenia
Neoplasms
Pharmaceutical Preparations

Keywords

  • adenocarcinoma of pancreas
  • fludarabine phosphate
  • phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Kilton, Lary J. ; Benson, Al B. ; Greenberg, Alice ; Johnson, Patricia ; Shapiro, Charles ; Blough, Richard ; French, Suzanne ; Weidner, Linda. / Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study. In: Investigational New Drugs. 1992 ; Vol. 10, No. 3. pp. 201-204.
@article{2ff850065efe4d8f9db1ee5c51abab7d,
title = "Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study",
abstract = "We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.",
keywords = "adenocarcinoma of pancreas, fludarabine phosphate, phase II trial",
author = "Kilton, {Lary J.} and Benson, {Al B.} and Alice Greenberg and Patricia Johnson and Charles Shapiro and Richard Blough and Suzanne French and Linda Weidner",
year = "1992",
month = "8",
day = "1",
doi = "10.1007/BF00877246",
language = "English (US)",
volume = "10",
pages = "201--204",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Kilton, LJ, Benson, AB, Greenberg, A, Johnson, P, Shapiro, C, Blough, R, French, S & Weidner, L 1992, 'Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study', Investigational New Drugs, vol. 10, no. 3, pp. 201-204. https://doi.org/10.1007/BF00877246

Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study. / Kilton, Lary J.; Benson, Al B.; Greenberg, Alice; Johnson, Patricia; Shapiro, Charles; Blough, Richard; French, Suzanne; Weidner, Linda.

In: Investigational New Drugs, Vol. 10, No. 3, 01.08.1992, p. 201-204.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study

AU - Kilton, Lary J.

AU - Benson, Al B.

AU - Greenberg, Alice

AU - Johnson, Patricia

AU - Shapiro, Charles

AU - Blough, Richard

AU - French, Suzanne

AU - Weidner, Linda

PY - 1992/8/1

Y1 - 1992/8/1

N2 - We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.

AB - We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.

KW - adenocarcinoma of pancreas

KW - fludarabine phosphate

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0026474964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026474964&partnerID=8YFLogxK

U2 - 10.1007/BF00877246

DO - 10.1007/BF00877246

M3 - Article

C2 - 1385353

AN - SCOPUS:0026474964

VL - 10

SP - 201

EP - 204

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -